PharmaCyte’s Innovative Platform Now Set to Target Multiple Deadly Cancers

BALTIMORE, MD / ACCESSWIRE / December 11, 2015 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new sponsored research article on PharmaCyte Biotech, Inc. (OTCQB – PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it and previous reports, updates, and articles in their entirety, please visit www.GoldmanResearch.com.

In the article, analyst Rob Goldman notes that since the Company’s Cell-in-a-Box(R) platform technology has proven to be effective in treating varying forms of cancer in preclinical and clinical tests, the platform could be potentially used to treat over 265,000 new patients suffering from varying forms of abdominal cancer and the 232,000 new patients diagnosed with breast cancer each year.

Goldman reported, “PharmaCyte’s live cell encapsulation technology, known as “Cell-in-a-Box(R)”, plus low-dose ifosfamide has successfully completed mid-stage clinical trials in pancreatic cancer. PharmaCyte could be just months away from a pre-IND meeting with the FDA to discuss plans for the next stage of clinical trials. Leveraging the solid results from completed trials and studies PharmaCyte initiated preclinical studies designed to determine the effectiveness of Cell-in-a-Box(R) plus ifosfamide therapy in delaying the accumulation of malignant ascites fluid in the abdomen of mice with abdominal tumors and a series of new studies are planned. According to management, if successful, PharmaCyte will have developed a treatment that will help combat the spread of abdominal tumors and reduce the suffering of cancer patients from the production of ascites fluid within the abdominal cavity.

“PharmaCyte’s platform technology plus low-dose ifosfamide has also achieved enviable success in efforts to develop a treatment for one of the most high profile cancers that are attributed to well over 200,000 new cases annually – breast cancer. As one might expect, the animal study results were remarkably similar to the earlier human Phase I/II pancreatic cancer trial using PharmaCyte’s platform technology,” commented Goldman.

Goldman continued, “Interestingly, prior to receiving approval for Abraxane as a treatment for pancreatic cancer, Celgene was awarded FDA approval to use the treatment for breast cancer. Since breast cancer is easier to treat and has a much higher survival rate than pancreatic cancer, it is conceivable that if PharmaCyte is successful in garnering FDA approval for pancreatic cancer, a breast cancer treatment approval could be a slam dunk. The bottom line is that if the favorable data from previous trials and studies for multiple cancer indications are any indication of potential future results, PharmaCyte’s novel approach could emerge as one of the most effective and diverse cancer treatment platforms in the market for solid tumors of all kinds and could be worth billions of dollars.”

About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co./p>

This press release contains excerpts of our most recently published sponsored research report on PharmaCyte Biotech, Inc. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from PharmaCyte Biotech Inc. (“the Company”) authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov.

Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com. In 2015, Goldman Small Cap Research has been compensated by a third party in the amount of $22,000 for investment research services that includes the publication of research reports, updates, and a series of articles.

About PharmaCyte Biotech.: PharmaCyte Biotech Inc. (OTCQB – PMCB) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box(R). This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. More information on PMCB can be found at www.PharmaCyteBiotech.com.

Goldman Small Cap Research
Rob Goldman, Analyst
410-609-7100
rob@goldmanresearch.com

SOURCE: PharmaCyte Biotech Inc.

ReleaseID: 434612